(Q43047740)

English

Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy

scientific article published on 2 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Masahiro Takita

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Satoru Hagiwara

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Tadaaki Arizumi

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sousuke Hayaishi

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Taisuke Ueda

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Satoshi Kitai

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Norihisa Yada

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Tatsuo Inoue

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yasunori Minami

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hobyung Chung

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Kazuomi Ueshima

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Toshiharu Sakurai

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

2 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

84 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

56-61

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Global burden of disease (GBD) for hepatitis C.

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Race, insulin resistance and hepatic steatosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?

1 reference

https://api.crossref.org/works/10.1159%2F000333215

21 January 2018

Identifiers

10.1159/000333215

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43047740&oldid=1978756071"